Nektar Therapeutics

The Phase 3 PIVOT IO-001 trial evaluating bempegaldesleukin in combination with Opdivo in untreated metastatic melanoma failed to meet its primary endpoints for progression-free survival and overall survival in 2022. Bristol Myers Squibb terminated the global clinical collaboration shortly after. The failure led to a major restructuring at Nektar, including a 70% workforce reduction in San Francisco.

Eli Lilly is Nektar's most significant current partner, holding global rights to rezpegaldesleukin (NKTR-358) for autoimmune indications. Pfizer previously licensed Nektar's anti-infectives portfolio and held a royalty position on Exubera, while Bristol Myers Squibb was the oncology partner on bempeg until the collaboration ended in 2022.

Nektar's technology attaches polyethylene glycol (PEG) polymers to therapeutic proteins to improve their pharmacokinetic profile — extending half-life and altering biodistribution. The platform was originally validated with PEGylated drugs like Neulasta (on-body injector) and later evolved into cytokine conjugates designed to bias immune signaling toward effector T-cells rather than regulatory T-cells.

Following the 2022 workforce reductions and an operational consolidation, the company disclosed roughly $350 million in cash and marketable securities as of mid-2023. Management has guided that this provides runway into 2026, concentrated on advancing the autoimmune-focused pipeline rather than re-initiating large oncology registration trials.

Nektar owns and operates a dedicated sterile-injectable manufacturing facility in Huntsville, Alabama, which handles the complex polymer conjugation and fill-finish for its clinical pipeline. This is a genuine differentiator from most mid-cap biotechs that rely entirely on CMOs for supply.

The lead autoimmune candidate, rezpegaldesleukin (partnered with Lilly), targets the IL-2 receptor to boost regulatory T-cells for immune suppression rather than stimulating killer T-cells as the oncology programs attempted. It is currently in Phase 2b for atopic dermatitis with additional studies planned in other autoimmune indications. The oncology pipeline has been substantially deprioritized.

Pfizer acquired Nektar's pulmonary anti-infectives platform in 2006 and later took on the inhaled-insulin product Exubera, paying Nektar royalties for years. That royalty stream historically provided a material non-dilutive cash flow to fund early oncology development, although it has since expired following patent cliffs.